Bone Biologics, which focuses on spinal orthobiologics, announced its underwritten public offering for $5.1 million total.
The company priced 3.7 million units of securities at $1.35 per share, according to an Oct. 7 news release.
Bone Biologics also granted underwriters the option to purchase up to 566,666 additional shares of common stock.